Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro

Cancer Biology and Therapy

Volumn 8, Issue 11, 2009, Pages 1018-1023

  Wang, Baofeng ^a   Han, Lin ^a   Chen, Rudong ^a   Cai, Mingjun ^a   Han, Fuxin ^a   Lei, Ting ^a   Guo, Dongsheng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Adhesion; EGFR; Glioma; Invasion; LRIG2; Proliferation; RNAi

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; LEUCINE RICH AND IMMUNOGLOBULIN LIKE DOMAIN 2 PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIGENE FAMILY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STATISTICAL ANALYSIS; WESTERN BLOTTING;

APOPTOSIS; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; GLIOBLASTOMA; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, NEOPLASM; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 68049137882     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.11.8375     Document Type: Article

References (29)

1. Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res 1998; 18:1303-11.
2. Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome? Strahlenther Onkol 2004; 180:401-7.
3. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170:1445-53.
4. Gil-Benso R, Lopez-Gines C, Benito R, Lopez-Guerrero JA, Callaghan RC, Pellin A, et al. Concurrent EGFR amplification and TP-53 mutation in glioblastomas. Clin Neuropathol 2007; 26:224-31.
5. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-24.
6. Guo D, Holmlund C, Henriksson R, Hedman H. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 2004; 84:157-65.
7. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R, et al. Characterization and tissue-specific expression of human LRIG2. Gene 2004; 332:35-43.
8. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004; 23:3270-81.
9. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL, 3rd, et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004; 279:47050-6.
10. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KL, 3rd, et al. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 2007; 27:1934-46.
11. Jensen KB, Watt FM. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence. Proc Natl Acad Sci USA 2006; 103:11958-63.
12. Hedman H, Nilsson J, Guo D, Henriksson R. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 2002; 41:352-4.
13. Law ME, Templeton KL, Kitange G, Smith J, Misra A, Feuerstein BG, et al. Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet Cytogenet 2005; 160:1-14.
14. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, et al. DNA copy number losses in human neoplasms. Am J Pathol 1999; 155:683-94.
15. Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H, et al. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 2006; 111:238-46.
16. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11.
17. Shen HL, Xu W, Wu ZY, Zhou LL, Qin RJ, Tang HR. Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF)165 expression in human leukemia cells. Leuk Res 2007; 31:515-21.
18. Yang WM, Yan ZJ, Ye ZQ, Guo DS. LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87. BJU Int 2006; 98:898-902.
19. Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 1986; 166:209-19.
20. Korkolopoulou P, Christodoulou P, Lekka-Katsouli I, Kouzelis K, Papanikolaou A, Panayotides I, et al. Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in gliomas. Histopathology 1994; 25:349-55.
21. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1:97-117.
22. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-7.
23. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55:178-94.
24. Shu HK, Kim MM, Chen P, Furman F, Julin CM, Israel MA. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21(BAX) expression. Proc Natl Acad Sci USA 1998; 95:14453-8.
25. Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr, Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 2003; 61:187-96.
26. Laws ER Jr, Shaffrey ME. The inherent invasiveness of cerebral gliomas: implications for clinical management. Int J Dev Neurosci 1999; 17:413-20.
27. Martens T, Laabs Y, Gunther HS, Kemming D, Zhu Z, Witte L, et al. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res 2008; 14:5447-58.
28. Holmlund C, Haapasalo H, Yi W, Raheem O, Brannstrom T, Bragge H, et al. Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology 2008; In press.
29. Bocchini V, Casalone R, Collini P, Rebel G, Lo Curto F. Changes in glial fibrillary acidic protein and karyotype during culturing of two cell lines established from human glioblasma multiforme. Cell Tissue Res 1991; 265:73-81.